Table 6.

Main Articles About Other Clinical Application of Remimazolam

Author (Year)	Procedure	Dose	Age (years)	Primary endpoint	Comparator	Co-treatment	Results
Horikoshi et al 202159	Single-incision laparoscopic percutaneous extraperitoneal closure in a pediatric with DMD	Induction: 3 mg Maintenance: 15 mg/h	4	Safety	N/A	Fentanyl (100 μg), maintained by remifentanil 1.0 µg/kg/min	Remimazolam can be safely used for general anesthesia in a pediatric patient with DMD
Petkus H et al 202258	Dental rehabilitation procedure in a pediatric suspected with family history of MH	5–7 µg/kg/min	6	Safety	N/A	Propofol (50 µg/kg/min)	Remimazolam was effective as an adjunct to propofol during general anesthesia in a pediatric suspected with family history of with MH
Kamata, K et al 202260	Supratentorial glioma resection under dc-MEP monitoring	0.9 mg/kg/h	12	Safety	N/A	Remifentanil (0.35 μg/kg/min)	Direct cortical MEP was successfully recorded in the pediatric patient under remimazolam anesthesia with cardiovascular stability
Yamadori, Y et al 202261	Open gastrostomy in a pediatric with MELAS	Induction: 0.2 mg/kg Maintenance: 2.0mg/kg/h	10	Safety	N/A	Remifentanil (0.3 μg/kg/min)	Remimazolam could be used in a pediatric with MELAS under general anesthesia without causing seizures and delayed emergence

Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; DMD, Duchenne muscular dystrophy; N, number of subjects; N/A, not available/applicable.